Trial Registration and Results Reporting

Imagine that a trial measures twenty outcomes and only one produces a striking favorable result. If researchers can declare that result the primary outcome after seeing the data, the published p value no longer has its intended meaning. If an unfavorable trial is never published, you see a distorted evidence base even when every published paper is accurate.

Prospective registration and results reporting create two public checkpoints. The first records what investigators planned before results were known. The second records what happened after the trial, even when a conventional article is delayed or absent.

Registration makes the original plan visible#

A trial registry assigns a persistent identifier and displays structured protocol fields. These typically include the scientific title, sponsor, and study design. They include intervention and comparator, eligibility criteria, and planned enrollment. They include recruitment status, primary and secondary outcomes, and outcome time frames. They include locations and contact information.

The timestamp is essential. A record created after data analysis can still help people find a study, but it cannot prove that the listed outcomes were chosen before results were seen.

Version history matters too. Legitimate trials change. Recruitment can be slower than expected, an instrument can become unavailable, or a safety committee can recommend modification. Transparent records preserve the original and revised entries, with dates and reasons, so you can judge whether a change was clinically justified or result driven.

Registration reduces several forms of bias#

Publication bias occurs when studies with statistically significant or favorable results are more likely to appear in journals, and selective outcome reporting occurs when measured outcomes are omitted, added, promoted, or demoted based on results. Selective time-point reporting chooses the most favorable follow-up.

A registry cannot force a journal to publish a manuscript. It can reveal that a study exists, what it planned to measure, when it ended, and whether summary results have been posted. Systematic reviewers can search for completed but unpublished trials and contact investigators.

Registration also helps potential participants find recruiting research, helps ethics committees see related studies, and can reduce unnecessary duplication. These benefits require accurate, complete, and current records. A vague outcome such as “safety will be assessed” is difficult to audit.

Legal requirements are narrower than ethical expectations#

FDAAA 801 and its implementing regulation at 42 CFR Part 11 establish United States requirements for certain “applicable clinical trials.” In general, these include specified interventional studies of FDA-regulated drugs, biologics, and devices, with exclusions and detailed jurisdictional tests.

Applicable clinical trials generally must be registered no later than 21 calendar days after enrollment of the first participant. Required results information is generally due no later than one year after the primary completion date, subject to particular certifications, extensions, and delayed-submission provisions.

The word “generally” is doing real work. Phase 1 drug studies and small device feasibility studies are commonly outside the federal definition, while certain device postmarket surveillance studies are covered. Product approval status, study location, and other criteria can affect obligations.

You should not infer that a trial lacked an ethical duty to report merely because a legal provision did not cover it. Nor should a sponsor assume that meeting a journal policy automatically meets federal law. Compliance requires trial-specific analysis by the responsible party.

NIH policy is broader than FDAAA in important ways#

The NIH Policy on Dissemination of NIH-Funded Clinical Trial Information applies to NIH-funded clinical trials within its scope, including studies that may not meet the federal “applicable clinical trial” definition. NIH expects registration and summary results submission to ClinicalTrials.gov.

NIH guidance identifies registration no later than 21 days after first participant enrollment and results no later than one year after the primary completion date, with limited exceptions, and the policy applies through award terms as well as any separate legal duties.

Basic experimental studies involving humans have had specific NIH enforcement flexibilities, including the possibility of alternative public platforms under designated conditions. That specialized policy should not be generalized to ordinary clinical trials. Funding source, study design, and award date therefore matter. “Not FDA regulated” does not necessarily mean “not required to register.”

ICMJE uses publication standards#

The International Committee of Medical Journal Editors recommends that journals require public registration at or before the time of first participant consent as a condition of manuscript consideration; that is earlier than the outer federal deadline of 21 days after first enrollment.

ICMJE accepts ClinicalTrials.gov and primary registries in the WHO International Clinical Trials Registry Platform network that meet specified standards and include the WHO minimum data set, and ethics approval alone does not satisfy the registration policy.

ICMJE defines clinical trials broadly as prospective assignment of people or groups to a health-related intervention to study a health outcome. Behavioral, educational, and dietary interventions can qualify, not only drug trials. So can quality-improvement and process-of-care interventions.

The policy is a publication standard, not a statute. A trial can be outside FDAAA but still risk rejection by an ICMJE journal if it was not prospectively registered. Rare exceptions should be explained publicly.

WHO links registries across countries#

The WHO International Clinical Trials Registry Platform provides a search portal and standards for a network of primary registries. It does not replace the originating record; it helps you search records from multiple jurisdictions.

The WHO trial registration data set aims to make core protocol information comparable. Universal Trial Numbers can support identification across systems, while the registration number from the primary registry remains important.

In a 2017 joint statement, WHO and major research funders called for prospective registration and public disclosure of results from funded trials, including summary results in a registry within 12 months and publication in a peer-reviewed journal within 24 months where possible.

International trials may face more than one regime. European Union rules, national laws, funder requirements, sponsor procedures, and journal policies can all apply. One ClinicalTrials.gov entry does not necessarily exhaust those obligations.

Results reporting is structured, not interpretive#

ClinicalTrials.gov results modules include participant flow, baseline characteristics, and outcome measures. They include statistical analyses, adverse events, and administrative information. The responsible party submits the data, and registry quality-control review can identify apparent errors or omissions before posting.

Quality-control review is not peer review and does not verify the source dataset. A posted result can still use a biased analysis, incomplete adverse-event capture, or a misleading outcome definition. Registry reviewers check conformance and apparent validity, not the full truth of the study.

Structured reporting has an important advantage: it demands tabular data for each prespecified measure and can be available without journal acceptance. Its disadvantage is limited narrative context. A thoughtful article can explain methods, uncertainty, protocol deviations, mechanisms, and limitations more fully. The best transparency gives you both, with consistent numbers and working links. Those links run among registry, protocol, and the statistical analysis plan. They run to the results record and publication.

Primary completion date is not study completion date#

The primary completion date is when the final participant was examined or received an intervention for collection of data for the primary outcome, and study completion includes final collection for primary and secondary outcomes and adverse events.

Because United States results deadlines often run from primary completion, confusing the two can move the deadline you think applies. A study can continue long-term follow-up after its primary results are due.

Responsible parties must update recruitment status and completion dates. Estimated dates should become actual dates when known. Stale “recruiting” records hide completed work and can mislead potential participants.

Outcome switching is not always misconduct#

Changing an outcome can be scientifically justified. A new consensus definition may emerge, an instrument may prove invalid, or an external event may make collection impossible. The problem is undisclosed, result-informed change.

Readers should compare the earliest complete registry version, the final protocol, and the statistical analysis plan. They should compare registry results and paper. Ask whether the primary outcome's wording, metric, and aggregation match what you are being shown. Ask the same of time frame and analysis population.

Subtle differences matter. “Depression at 12 weeks” is not the same as “change in depression score from baseline to the best visit between 8 and 16 weeks.” A composite outcome can change if one component is added. A safety outcome can become narrower through a revised definition.

If a change was made before unblinding and documented with a reason, it may improve the study, and if the paper silently promotes a favorable secondary outcome, interpretation should be cautious even if the analysis itself is correct.

Registration does not prevent poor design#

A prospectively registered trial can be underpowered, use an invalid surrogate, or choose a weak comparator. It can have excessive missing data or analyze outcomes incorrectly. Registration makes decisions visible; it does not make them wise.

Nor does registration establish that enrollment occurred as planned. Trials terminate early, miss targets, and change sites. They stop for futility, harm, benefit, or business reasons. The status and history must be read. A registry can also contain duplicate entries for the same trial, especially across national systems. Match sponsor, interventions, and sample size. Match dates, sites, and identifiers so you do not count one trial twice.

Common red flags in a registry audit#

Red flags include registration after enrollment began, an outcome without a specific metric or time frame, large unexplained sample-size changes, a completed trial with no results long after the expected deadline, and a paper whose primary outcome is absent from the earliest record.

Other concerns include a study marked “unknown status,” a completion date repeatedly pushed forward, adverse events reported in a paper but not the registry, or inconsistent participant counts across flow tables.

None proves wrongdoing by itself. Administrative errors, mergers, investigator turnover, legitimate amendments, and registry migration can produce discrepancies. The appropriate response is documented inquiry and cautious synthesis, not automatic accusation.

How systematic reviewers should use records#

Search registries using disease terms, intervention names, sponsor names, and identifiers from papers. Download version histories where available. Contact responsible parties for completed studies without public results.

Use the registry to identify prespecified outcomes and missing studies, then assess risk of bias with a suitable tool. Do not replace a full report with a one-line recruitment status when richer data exist.

When registry results and publication differ, report the discrepancy and decide in advance which source or rule governs extraction. Selectively choosing whichever version favors a hypothesis recreates the bias the audit is meant to prevent.

Responsibilities continue after posting#

Records need corrections when errors are found, links to resulting publications, and updates when results change. Sponsors should preserve protocol versions, analysis plans, and clear ownership during staff transitions.

Institutions and funders need dashboards that identify approaching deadlines and unresolved quality-control comments. Waiting until a grant report or journal submission to discover an overdue record is avoidable.

Participants contribute time and accept risk partly to create generalizable knowledge. Timely public results honor that contribution. Registration begins the transparency obligation; it does not complete it.

References#

1. NIH trial registration and reporting requirements
2. 42 CFR Part 11 Final Rule
3. ClinicalTrials.gov FDAAA 801 and Final Rule guide
4. ICMJE clinical-trial registration recommendations
5. WHO International Clinical Trials Registry Platform
6. WHO joint statement on registration and public disclosure of trial results